BioWorld

Feb. 23, 2010

Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today) Read More

FDA Raises Endpoint Concerns in Study of Salix Liver Drug

Blocking Backup Pathway Could Prevent Glioblastoma Comeback

New Money Scarce, so ITS Founders Chip in $13.4M

Icahn Makes Move as Genzyme Looks for Good News in 2010

White House Health Bill Adopts 12 Years for FOBs

NIH Stem Cell Definition Change 'Hugely Important'

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...